CTOs on the Move

Lion Biotechnologies

www.lbio.com

 
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.lbio.com
  • 21900 Burbank Blvd. Third Floor
    Woodland Hills, CA USA 91367
  • Phone: 818.992.3126

Executives

Name Title Contact Details

Similar Companies

AbCellera

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

ReproSource

ReproSource is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mendel Biotechnology

Mendel Biotechnology is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

ACT Services

ACT Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases